{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:58:18Z","timestamp":1776772698673,"version":"3.51.2"},"reference-count":371,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Errors are very common in medical practice and in particular, in the healthcare of patients with inflammatory bowel disease (IBD); however, most of these can be prevented. Aim: To address common errors in the management of IBD. Methods: Our approach to this problem consists in identifying mistakes frequently observed in clinical practice (according to our experience) in the management of patients with IBD, then reviewing the scientific evidence available on the subject, and finally proposing the most appropriate recommendation for each case. Results: The most common mistakes in the management of IBD include those related to diagnosis and differential diagnosis, prevention, nutrition and diet, treatment with different drugs (mainly 5-aminosalicylates, corticosteroids, thiopurines, and anti-TNF agents), extraintestinal manifestations, anemia, elderly patients, pregnancy, and surgery. Conclusions: Despite the availability of guidelines for both disease management and preventive aspects of IBD care, a considerable variation in clinical practice still remains. In this review, we have identified common mistakes in the management of patients with IBD in clinical practice. There is a clear need for a greater dissemination of clinical practice guidelines among gastroenterologists and for the implementation of ongoing training activities supported by scientific societies. Finally, it is desirable to follow IBD patients in specialized units, which would undoubtedly be associated with higher-quality healthcare and a lower likelihood of errors in managing these patients.<\/jats:p>","DOI":"10.3390\/jcm13164795","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T03:49:36Z","timestamp":1723693776000},"page":"4795","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Common Mistakes in Managing Patients with Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P.","family":"Gisbert","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4242","authenticated-orcid":false,"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMsa054479","article-title":"Claims, errors, and compensation payments in medical malpractice litigation","volume":"354","author":"Studdert","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/bmj.320.7237.781","article-title":"On error management: Lessons from aviation","volume":"320","author":"Helmreich","year":"2000","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/bmj.320.7237.768","article-title":"Human error: Models and management","volume":"320","author":"Reason","year":"2000","journal-title":"BMJ"},{"key":"ref_4","first-page":"56","article-title":"Safety in the operating theatre\u2014Part 2: Human error and organisational failure","volume":"14","author":"Reason","year":"2005","journal-title":"Qual. Saf. Health Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJMsb051157","article-title":"Accidental deaths, saved lives, and improved quality","volume":"353","author":"Brennan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"Kohn, L.T., Corrigan, J.M., and Donaldson, M.S. (1999). To Err Is Human: Building a Safer Health System, National Academies Press."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1365-2036.2007.03445.x","article-title":"Differences in the management of Crohn\u2019s disease among experts and community providers, based on a national survey of sample case vignettes","volume":"26","author":"Esrailian","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.crohns.2010.06.001","article-title":"Adherence of gastroenterologists to European Crohn\u2019s and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain","volume":"4","author":"Gisbert","year":"2010","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.crohns.2011.12.013","article-title":"Adherence of gastroenterologists to European Crohn\u2019s and Colitis Organisation consensus on Crohn\u2019s disease: A real-life survey in Spain","volume":"6","author":"Hinojosa","year":"2012","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cgh.2008.08.029","article-title":"Controversies in ulcerative colitis: A survey comparing decision making of experts versus community gastroenterologists","volume":"7","author":"Spiegel","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00005650-198505000-00030","article-title":"Efficacy, effectiveness, variations, and quality. Boundary-crossing research","volume":"23","author":"Brook","year":"1985","journal-title":"Med. Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/intqhc\/12.4.281","article-title":"Defining and measuring quality of care: A perspective from US researchers","volume":"12","author":"Brook","year":"2000","journal-title":"Int. J. Qual. Health Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00054725-200305000-00011","article-title":"Ten common errors in the management of inflammatory bowel disease","volume":"9","author":"Sachar","year":"2003","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1157\/13101982","article-title":"Common errors in the management of the seriously ill patient with inflammatory bowel disease","volume":"30","author":"Gisbert","year":"2007","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1157\/13110491","article-title":"Common errors in the management of outpatients with inflammatory bowel disease","volume":"30","author":"Gisbert","year":"2007","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_16","first-page":"200","article-title":"Common Pitfalls in Management of Inflammatory Bowel Disease","volume":"2","author":"Pasumarthy","year":"2009","journal-title":"Gastroenterol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2011.02.045","article-title":"Conventional medical management of inflammatory bowel disease","volume":"140","author":"Burger","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/gut.2010.218180","article-title":"Current misunderstandings in the management of ulcerative colitis","volume":"60","author":"Ochsenkuhn","year":"2011","journal-title":"Gut"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.cgh.2023.09.043","article-title":"Common Instances of Low-value Care in Inflammatory Bowel Diseases","volume":"22","author":"Singh","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00042737-200603000-00004","article-title":"Optimizing quality of outpatient care for patients with inflammatory bowel disease: The importance of specialist clinics","volume":"18","author":"Mawdsley","year":"2006","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1572-0241.2005.40849.x","article-title":"Are patients with inflammatory bowel disease receiving optimal care?","volume":"100","author":"Reddy","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.gastrohep.2019.11.001","article-title":"Errors in the care of inflammatory bowel disease patients: \u201cErrata\u201d Study","volume":"43","author":"Casanova","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/00365521.2017.1278785","article-title":"Clinicians\u2019 adherence to international guidelines in the clinical care of adults with inflammatory bowel disease","volume":"52","author":"Jackson","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Watanabe, K., Gardiner, S., and Arai, S. (2022). Notable gaps between patients\u2019 and physicians\u2019 perspectives on communication and disease management in Japan: Multifaceted ad hoc analyses of the global Ulcerative Colitis Narrative Survey for further optimal care. Therap. Adv. Gastroenterol., 15.","DOI":"10.1177\/17562848221095372"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-7125(16)30584-3","article-title":"Infectious causes of diarrhea in the differential diagnosis of inflammatory bowel disease","volume":"74","author":"Farmer","year":"1990","journal-title":"Med. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00054725-200205000-00009","article-title":"Role of infections in the manifestation or reactivation of inflammatory bowel diseases","volume":"8","author":"Stallmach","year":"2002","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bpg.2018.05.007","article-title":"Acute severe ulcerative colitis: State of the art treatment","volume":"32\u201333","author":"Gisbert","year":"2018","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/01.mcg.0000139057.05297.d6","article-title":"The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease","volume":"38","author":"Meyer","year":"2004","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_29","first-page":"168","article-title":"Estudio prospectivo sobre la incidencia de infecci\u00f3n gastrointestinal por enteropat\u00f3genos en pacientes con enfermdad inflamatoria intestinal en brote de actividad","volume":"28","author":"Navarro","year":"2006","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14787210.2024.2347955","article-title":"Clostridioides difficile infection in inflammatory bowel disease: A clinical review","volume":"22","author":"Tang","year":"2024","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0016-5085(81)90127-X","article-title":"Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease","volume":"80","author":"Trnka","year":"1981","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.24.8.713","article-title":"Clostridium difficile and inflammatory bowel disease","volume":"24","author":"Greenfield","year":"1983","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1017\/ice.2014.39","article-title":"Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: A systematic review and meta-analysis","volume":"36","author":"Stone","year":"2015","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2017.04.044","article-title":"Higher Incidence of Clostridium difficile Infection Among Individuals with Inflammatory Bowel Disease","volume":"153","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00384-018-3105-8","article-title":"Impact of superimposed Clostridium difficile infection in Crohn\u2019s or ulcerative colitis flares in the outpatient setting","volume":"33","author":"Garcia","year":"2018","journal-title":"Int. J. Color. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjy143","article-title":"Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"13","author":"Balram","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/1751-2980.12798","article-title":"High incidence and morbidity of Clostridium difficile infection among hospitalized patients with inflammatory bowel disease: A prospective observational cohort study","volume":"20","author":"Chen","year":"2019","journal-title":"J. Dig. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1097\/MIB.0000000000001251","article-title":"Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease: A Propensity Score Matched Analysis","volume":"23","author":"Anderson","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12328-017-0719-2","article-title":"Clostridium difficile infection in inflammatory bowel disease: Challenges in diagnosis and treatment","volume":"10","author":"Tang","year":"2017","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ecco-jcc\/jjab141","article-title":"ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease","volume":"16","author":"Feakins","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_43","first-page":"182","article-title":"Sexually transmitted infections as a differential diagnosis of inflammatory bowel disease","volume":"47","author":"Gisbert","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/MIB.0000000000000726","article-title":"How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD","volume":"22","author":"Chachu","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0016-5107(83)72583-6","article-title":"Infectious colitis endoscopically simulating inflammatory bowel disease: A prospective evaluation","volume":"29","author":"Tedesco","year":"1983","journal-title":"Gastrointest. Endosc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMra1907194","article-title":"Emerging and Reemerging Sexually Transmitted Infections","volume":"382","author":"Williamson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PAP.0000000000000014","article-title":"Sex, lies, and gastrointestinal tract biopsies: A review of selected sexually transmitted proctocolitides","volume":"21","author":"Voltaggio","year":"2014","journal-title":"Adv. Anat. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-2007-1018366","article-title":"Bioptic microbiology in the differential diagnosis of enterocolitis","volume":"18","author":"Bayerdorffer","year":"1986","journal-title":"Endoscopy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000199823","article-title":"Clinical and prognostic features of rectal sparing in ulcerative colitis","volume":"42","author":"Oshitani","year":"1989","journal-title":"Digestion"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00000478-199309000-00002","article-title":"Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis","volume":"17","author":"Odze","year":"1993","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0016-5107(95)70097-8","article-title":"Patchiness of mucosal inflammation in treated ulcerative colitis: A prospective study","volume":"42","author":"Bernstein","year":"1995","journal-title":"Gastrointest. Endosc."},{"key":"ref_52","first-page":"1275","article-title":"Patchy cecal inflammation associated with distal ulcerative colitis: A prospective endoscopic study","volume":"92","author":"Geboes","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1572-0241.1998.00695.x","article-title":"Ulcerative colitis with skip lesions at the mouth of the appendix: A clinical study","volume":"93","author":"Okawa","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1365-2559.1998.00477.x","article-title":"Appendiceal inflammation in ulcerative colitis","volume":"33","author":"Scott","year":"1998","journal-title":"Histopathology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1111\/j.1572-0241.1999.01533.x","article-title":"Endoscopic and histological patchiness in treated ulcerative colitis","volume":"94","author":"Kim","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0016-5107(99)70293-2","article-title":"Appendiceal orifice inflammation as a skip lesion in ulcerative colitis: An analysis in relation to medical therapy and disease extent","volume":"49","author":"Yang","year":"1999","journal-title":"Gastrointest. Endosc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/003655202753416849","article-title":"Clinical and colonoscopic investigation of skipped periappendiceal lesions in ulcerative colitis","volume":"37","author":"Yamagishi","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mge.2002.121335","article-title":"Significance of appendiceal involvement in patients with ulcerative colitis","volume":"55","author":"Matsumoto","year":"2002","journal-title":"Gastrointest. Endosc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0210-5705(03)79045-1","article-title":"Ulcerative colitis with segmental involvement","volume":"26","author":"Dolz","year":"2003","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/01.MIB.0000164018.06538.6e","article-title":"Clinical course of distal ulcerative colitis in relation to appendiceal orifice inflammation status","volume":"11","author":"Byeon","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can. J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/gut.32.2.183","article-title":"Morphometric studies in rectal biopsy specimens from patients with ulcerative colitis: Effect of oral 5 amino salicylic acid and rectal prednisolone treatment","volume":"32","author":"Zaitoun","year":"1991","journal-title":"Gut"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1542-3565(04)00441-0","article-title":"Endoscopy in inflammatory bowel disease: Indications, surveillance, and use in clinical practice","volume":"3","author":"Fefferman","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ibd.21847","article-title":"Toxic megacolon","volume":"18","author":"Autenrieth","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0210-5705(02)70313-0","article-title":"Treatment of stenosis due to Crohn\u2019s disease","volume":"25","author":"Gisbert","year":"2002","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0002-9610(02)00879-6","article-title":"Acute surgical emergencies in inflammatory bowel disease","volume":"184","author":"Berg","year":"2002","journal-title":"Am. J. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/j.1572-0241.2003.07696.x","article-title":"A new look at toxic megacolon: An update and review of incidence, etiology, pathogenesis, and management","volume":"98","author":"Gan","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2147\/IDR.S149784","article-title":"Is cytomegalovirus infection related to inflammatory bowel disease, especially steroid-resistant inflammatory bowel disease? A meta-analysis","volume":"10","author":"Lv","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1097\/MIB.0000000000000489","article-title":"Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis","volume":"21","author":"Shukla","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00054725-200405000-00011","article-title":"The pathogenicity of cytomegalovirus in inflammatory bowel disease: A systematic review and evidence-based recommendations for future research","volume":"10","author":"Hommes","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2005.02424.x","article-title":"Review article: Smoking cessation as primary therapy to modify the course of Crohn\u2019s disease","volume":"21","author":"Johnson","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ibd.22959","article-title":"Does smoking influence Crohn\u2019s disease in the biologic era? The TABACROHN study","volume":"19","author":"Nunes","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/ecco-jcc\/jjv113","article-title":"High Rates of Smoking Especially in Female Crohn\u2019s Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation\u2014Data from the Swiss IBD Cohort Study","volume":"9","author":"Biedermann","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/MEG.0000000000000371","article-title":"Beliefs and behaviour about smoking among inflammatory bowel disease patients","volume":"27","author":"Saadoune","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.crohns.2012.04.011","article-title":"High smoking cessation rate in Crohn\u2019s disease patients after physician advice\u2014The TABACROHN Study","volume":"7","author":"Nunes","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/ecco-jcc\/jjx022","article-title":"Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease","volume":"11","author":"Taxonera","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.gastrohep.2020.04.006","article-title":"Recommendations of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease","volume":"44","author":"Riestra","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrgastro.2013.28","article-title":"Vaccination strategies in patients with IBD","volume":"10","author":"Gisbert","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2036.2010.04570.x","article-title":"Review article: Prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease","volume":"33","author":"Gisbert","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MCG.0000000000000758","article-title":"Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated with Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"51","author":"Shukla","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.crohns.2014.06.009","article-title":"Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)","volume":"8","author":"Loras","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","article-title":"Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease","volume":"21","author":"Marin","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/gut.2006.114660","article-title":"Opportunistic infections in patients with inflammatory bowel disease: Prevention and diagnosis","volume":"57","author":"Viget","year":"2008","journal-title":"Gut"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","article-title":"Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses","volume":"101","author":"Melmed","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/ibd.21667","article-title":"Vaccinating the inflammatory bowel disease patient: Deficiencies in gastroenterologists knowledge","volume":"17","author":"Wasan","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5009\/gnl.2014.8.3.242","article-title":"Insufficient knowledge of korean gastroenterologists regarding the vaccination of patients with inflammatory bowel disease","volume":"8","author":"Jung","year":"2014","journal-title":"Gut Liver"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/postgradmedj-2016-134266","article-title":"Vaccination practices in patients with inflammatory bowel disease among general internal medicine physicians in the USA","volume":"93","author":"Gurvits","year":"2017","journal-title":"Postgrad. Med. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1016\/j.crohns.2013.02.019","article-title":"Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease","volume":"7","author":"Walsh","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00054725-200409000-00028","article-title":"Guidelines for immunizations in patients with inflammatory bowel disease","volume":"10","author":"Sands","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ajcn\/60.5.775","article-title":"Mechanisms of decreased food intake during weight loss in adult Crohn\u2019s disease patients without obvious malabsorption","volume":"60","author":"Rigaud","year":"1994","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ibd.22965","article-title":"Dietary beliefs and behavior among inflammatory bowel disease patients","volume":"19","author":"Zallot","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/ecco-jcc\/jjx102","article-title":"Prevalence of Malnutrition and Nutritional Characteristics of Patients with Inflammatory Bowel Disease","volume":"11","author":"Casanova","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0261-5614(03)00132-8","article-title":"Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake","volume":"23","author":"Jowett","year":"2004","journal-title":"Clin. Nutr."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MIB.0000000000000585","article-title":"Dietary Practices and Beliefs in Patients with Inflammatory Bowel Disease","volume":"22","author":"Limdi","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Day, A.S., Yao, C.K., Costello, S.P., Andrews, J.M., and Bryant, R.V. (2021). Food avoidance, restrictive eating behaviour and association with quality of life in adults with inflammatory bowel disease: A systematic scoping review. Appetite, 167.","DOI":"10.1016\/j.appet.2021.105650"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2013.09.063","article-title":"Diet and inflammatory bowel disease: Review of patient-targeted recommendations","volume":"12","author":"Hou","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ajcn\/65.2.564","article-title":"Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease","volume":"65","author":"Mishkin","year":"1997","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/ecco-jcc\/jjw106","article-title":"IBD: In Food We Trust","volume":"10","author":"Savoye","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2023.11.303","article-title":"AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients with Inflammatory Bowel Disease: Expert Review","volume":"166","author":"Hashash","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/0016-5085(80)90913-0","article-title":"Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis","volume":"79","author":"Dickinson","year":"1980","journal-title":"Gastroenterology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/gut.27.5.481","article-title":"Controlled trial of bowel rest in the treatment of severe acute colitis","volume":"27","author":"McIntyre","year":"1986","journal-title":"Gut"},{"key":"ref_105","first-page":"227","article-title":"Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis","volume":"88","author":"Cabre","year":"1993","journal-title":"Am. J. Gastroenterol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2004.02050.x","article-title":"Review article: The role of nutrition in the treatment of inflammatory bowel disease","volume":"20","author":"Gassull","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/BF02051922","article-title":"The starved colon\u2014Diminished mucosal nutrition, diminished absorption, and colitis","volume":"33","author":"Roediger","year":"1990","journal-title":"Dis. Colon. Rectum"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bpg.2006.03.001","article-title":"Nutrition in inflammatory bowel disease","volume":"20","year":"2006","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1017987229718","article-title":"Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: A systematic review","volume":"47","author":"Gisbert","year":"2002","journal-title":"Dig. Dis. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/14656566.2016.1187132","article-title":"Maintenance therapy options for ulcerative colitis","volume":"17","author":"Chaparro","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.3748\/wjg.v17.i30.3467","article-title":"Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease","volume":"17","author":"Gisbert","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1053\/j.gastro.2021.04.023","article-title":"AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease","volume":"160","author":"Singh","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn\u2019s disease: A meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., and Warusavitarne, J. (2024). ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. J. Crohn\u2019s Colitis, in press.","DOI":"10.1093\/ecco-jcc\/jjae091"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Lim, W.C., Wang, Y., MacDonald, J.K., and Hanauer, S. (2016). Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Cochrane Database Syst. Rev., 7.","DOI":"10.1002\/14651858.CD008870.pub2"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1097\/MIB.0000000000001158","article-title":"Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn\u2019s Disease: A Bayesian Network Meta-analysis: Republished","volume":"23","author":"Coward","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/apt.13190","article-title":"Systematic review with network meta-analysis: Comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn\u2019s disease","volume":"41","author":"Moja","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Akobeng, A.K., Zhang, D., Gordon, M., and MacDonald, J.K. (2016). Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease. Cochrane Database Syst. Rev., 9.","DOI":"10.1002\/14651858.CD003715.pub3"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Gjuladin-Hellon, T., Gordon, M., Iheozor-Ejiofor, Z., and Akobeng, A.K. (2019). Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn\u2019s disease. Cochrane Database Syst. Rev., 6.","DOI":"10.1002\/14651858.CD008414.pub3"},{"key":"ref_122","first-page":"CD008414","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn\u2019s disease","volume":"1","author":"Gordon","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/gut.33.10.1338","article-title":"Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations","volume":"33","author":"Verdievel","year":"1992","journal-title":"Gut"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2036.2000.00697.x","article-title":"Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis","volume":"14","author":"Hebden","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1007\/BF01308084","article-title":"Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis","volume":"37","author":"Campieri","year":"1992","journal-title":"Dig. Dis. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1046\/j.1365-2036.1999.00642.x","article-title":"Rectal and colonic mesalazine concentration in ulcerative colitis: Oral vs. oral plus topical treatment","volume":"13","author":"Frieri","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.gastrohep.2019.10.004","article-title":"Recommendations of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis","volume":"43","author":"Ginard","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gastrohep.2020.07.001","article-title":"GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach","volume":"43","author":"Sicilia","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","article-title":"A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis","volume":"95","author":"Cohen","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"ref_131","first-page":"1867","article-title":"A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2036.2001.00913.x","article-title":"Oral versus combination mesalazine therapy in active ulcerative colitis: A double-blind, double-dummy, randomized multicentre study","volume":"15","author":"Vecchi","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_133","first-page":"473","article-title":"On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending4 colon","volume":"27","author":"Fruhmorgen","year":"1980","journal-title":"Hepatogastroenterology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000235916","article-title":"Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis","volume":"80","author":"Connolly","year":"2009","journal-title":"Digestion"},{"key":"ref_135","first-page":"1143","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double-blind study","volume":"92","author":"Pacini","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/00365520310008133","article-title":"Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis","volume":"39","author":"Piodi","year":"2004","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-2036.1997.tb00001.x","article-title":"Oral or rectal administration of drugs in IBD?","volume":"11","author":"Moody","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.dld.2004.09.017","article-title":"Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis","volume":"37","author":"Frieri","year":"2005","journal-title":"Dig. Liver Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2036.2006.02809.x","article-title":"Systematic review: Adherence issues in the treatment of ulcerative colitis","volume":"23","author":"Kane","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2036.2006.03060.x","article-title":"Review article: How to control and improve adherence to therapy in inflammatory bowel disease","volume":"24","author":"Bermejo","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2036.2001.00891.x","article-title":"Once versus divided daily dosing with delayed-release mesalazine: A study of tissue drug concentrations and standard pharmacokinetic parameters","volume":"15","author":"Hussain","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/0091270006296522","article-title":"Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers","volume":"47","author":"Gandia","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_143","first-page":"136","article-title":"A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy","volume":"16","author":"Parakkal","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/ajg.2011.296","article-title":"Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: Systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"O214","DOI":"10.1111\/codi.13393","article-title":"Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: A meta-analysis","volume":"18","author":"Li","year":"2016","journal-title":"Color. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Wang, Y., Parker, C.E., Feagan, B.G., and MacDonald, J.K. (2016). Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2016.","DOI":"10.1002\/14651858.CD000544.pub4"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Murray, A., Nguyen, T.M., Parker, C.E., Feagan, B.G., and MacDonald, J.K. (2020). Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., 8.","DOI":"10.1002\/14651858.CD000543.pub5"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Murray, A., Nguyen, T.M., Parker, C.E., Feagan, B.G., and MacDonald, J.K. (2020). Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev., 8.","DOI":"10.1002\/14651858.CD000544.pub5"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2009.04.004","article-title":"Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis","volume":"7","author":"Dignass","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jgh.15458","article-title":"Common mistakes with steroids","volume":"36","author":"An","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.gastrohep.2022.10.017","article-title":"Corticosteroids in inflammatory bowel disease: Are they still a therapeutic option?","volume":"46","author":"Quera","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Steinhart, A.H., Ewe, K., Griffiths, A.M., Modigliani, R., and Thomsen, O.O. (2003). Corticosteroids for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD000301"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2019.8506","article-title":"Steroid Side Effects","volume":"322","author":"Grennan","year":"2019","journal-title":"JAMA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjy140","article-title":"\u2018Quality of Care\u2019 Standards in Inflammatory Bowel Disease: A Systematic Review","volume":"13","author":"Fiorino","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ecco-jcc\/jjaa023","article-title":"Quality of Care Standards in Inflammatory Bowel Diseases: A European Crohn\u2019s and Colitis Organisation [ECCO] Position Paper","volume":"14","author":"Fiorino","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ueg2.12105","article-title":"Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience","volume":"9","author":"Gutierrez","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1542-3565(03)00185-X","article-title":"Risk of fracture in ulcerative colitis: A population-based study from Olmsted County, Minnesota","volume":"1","author":"Loftus","year":"2003","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/apt.14334","article-title":"A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease","volume":"46","author":"Selinger","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/apt.15497","article-title":"Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients","volume":"50","author":"Selinger","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Sicilia, B., Arias, L., Hontoria, G., Garcia, N., Badia, E., and Gomollon, F. (2021). Are Steroids Still Useful in Immunosuppressed Patients with Inflammatory Bowel Disease? A Retrospective, Population-Based Study. Front. Med., 8.","DOI":"10.3389\/fmed.2021.651685"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.13700","article-title":"Steroid dependency and trends in prescribing for inflammatory bowel disease\u2014A 20-year national population-based study","volume":"44","author":"Chhaya","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/apt.12727","article-title":"Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn\u2019s disease","volume":"39","author":"Rubin","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious Infection and Mortality in Patients with Crohn\u2019s Disease: More Than 5 Years of Follow-Up in the TREAT Registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s12325-016-0393-7","article-title":"Gastroenterologists\u2019 Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey","volume":"33","author":"Lasch","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40268-019-0263-2","article-title":"Ulcerative Colitis: Shifting Sands","volume":"19","author":"Lindsay","year":"2019","journal-title":"Drugs R&D"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.cgh.2020.06.036","article-title":"Effect of Concomitant Therapy with Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients with Crohn\u2019s Disease: A Systematic Review and Pooled Meta-analysis","volume":"19","author":"Faleck","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/bmj.2.5302.441","article-title":"Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone","volume":"5302","author":"Baron","year":"1962","journal-title":"Br. Med. J."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00004836-199002000-00011","article-title":"High-dose methylprednisolone in the treatment of active ulcerative colitis","volume":"12","author":"Rosenberg","year":"1990","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0016-5085(83)90323-2","article-title":"Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial","volume":"85","author":"Meyers","year":"1983","journal-title":"Gastroenterology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0016-5085(85)90201-X","article-title":"Intensive intravenous treatment of ulcerative colitis","volume":"89","author":"Jarnerot","year":"1985","journal-title":"Gastroenterology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/0016-5085(93)90738-X","article-title":"Clinical and colonoscopic surveillance in ulcerative colitis: Are we saving colons or saving lives?","volume":"105","author":"Sachar","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2036.2006.03064.x","article-title":"Review article: Saving the colon in severe colitis\u2014The case for medical therapy","volume":"24","author":"Travis","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI200418975","article-title":"Enhancement of MEK\/ERK signaling promotes glucocorticoid resistance in CD4+ T cells","volume":"113","author":"Tsitoura","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4321\/S1130-01082005001100006","article-title":"Bone metabolism changes in patients with inflammatory bowel disease","volume":"97","author":"Legido","year":"2005","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-112-5-352","article-title":"Glucocorticoid-induced osteoporosis: Pathogenesis and management","volume":"112","author":"Lukert","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/gast.2003.50106","article-title":"AGA technical review on osteoporosis in gastrointestinal diseases","volume":"124","author":"Bernstein","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/MIB.0000000000000815","article-title":"Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease: A 5-Year Prospective Study","volume":"22","author":"Chaparro","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Leufkens","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1053\/gast.2000.19280","article-title":"Bone mineral density in patients with recently diagnosed inflammatory bowel disease","volume":"119","author":"Schoon","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.dld.2017.07.005","article-title":"The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey","volume":"49","author":"Meucci","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"ref_186","first-page":"CD000067","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease","volume":"2015","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.gastrohep.2017.11.007","article-title":"Recommendations of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease","volume":"41","author":"Bermejo","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0210-5705(02)70275-6","article-title":"Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease","volume":"25","author":"Gisbert","year":"2002","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/apt.12511","article-title":"A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: An observational study, systematic review and meta-analysis","volume":"38","author":"Kennedy","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2036.2008.03746.x","article-title":"Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis","volume":"28","author":"Bermejo","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/ecco-jcc\/jjaa055","article-title":"Switching to a Second Thiopurine in Adult and Elderly Patients with Inflammatory Bowel Disease: A Nationwide Study from the ENEIDA Registry","volume":"14","author":"Calafat","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1572-0241.2007.01187.x","article-title":"Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review","volume":"102","author":"Gisbert","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_194","first-page":"1711","article-title":"The long-term outcome of ulcerative colitis treated with 6- mercaptopurine","volume":"91","author":"George","year":"1996","journal-title":"Am. J. Gastroenterol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn\u2019s disease","volume":"119","author":"Markowitz","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0016-5085(91)90457-V","article-title":"Use of azathioprine or 6-mercaptopurine in the treatment of Crohn\u2019s disease","volume":"101","author":"Bayless","year":"1991","journal-title":"Gastroenterology"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2036.2005.02636.x","article-title":"Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease","volume":"22","author":"Bastida","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ibd.20160","article-title":"Liver injury in inflammatory bowel disease: Long-term follow-up study of 786 patients","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2036.2004.02030.x","article-title":"Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis","volume":"20","author":"Bermejo","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/pds.926","article-title":"Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease","volume":"13","author":"Gearry","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2036.2008.03925.x","article-title":"Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease","volume":"29","author":"Hindorf","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2036.2009.04132.x","article-title":"Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease","volume":"31","author":"Bermejo","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","article-title":"Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review","volume":"103","author":"Gisbert","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.34.8.1081","article-title":"Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience","volume":"34","author":"Connell","year":"1993","journal-title":"Gut"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn\u2019s disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0016-5085(98)70251-3","article-title":"Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease","volume":"115","author":"Kirschner","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Khosrotehrani","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2009.05.025","article-title":"A new answer to an old question: Azathioprine withdrawal in quiescent Crohn\u2019s disease","volume":"137","author":"Sewell","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0140-6736(96)90402-X","article-title":"Long-term follow-up of patients with Crohn\u2019s disease treated with azathioprine or 6-mercaptopurine","volume":"347","author":"Bouhnik","year":"1996","journal-title":"Lancet"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","article-title":"A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine","volume":"128","author":"Lemann","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2008.08.028","article-title":"Azathioprine withdrawal in patients with Crohn\u2019s disease maintained on prolonged remission: A high risk of relapse","volume":"7","author":"Treton","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_213","first-page":"955","article-title":"Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn\u2019s disease","volume":"2","author":"Dawson","year":"1978","journal-title":"Lancet"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s10620-014-3419-5","article-title":"Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn\u2019s disease","volume":"60","author":"Wenzl","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2004.01944.x","article-title":"Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn\u2019s disease: Increased relapse rate the following year","volume":"19","author":"Vilien","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s10620-011-1671-5","article-title":"Relapse rate following azathioprine withdrawal in maintaining remission for Crohn\u2019s disease: A meta-analysis","volume":"56","author":"French","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.305.6844.20","article-title":"Randomised controlled trial of azathioprine withdrawal in ulcerative colitis","volume":"305","author":"Hawthorne","year":"1992","journal-title":"BMJ"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1038\/ajg.2009.410","article-title":"Maintenance treatment with azathioprine in ulcerative colitis: Outcome and predictive factors after drug withdrawal","volume":"104","author":"Cassinotti","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review","volume":"50","author":"Fraser","year":"2002","journal-title":"Gut"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation Topical Review on Treatment Withdrawal [\u2018Exit Strategies\u2019] in Inflammatory Bowel Disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/ecco-jcc\/jjz158","article-title":"The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn\u2019s Disease","volume":"14","author":"Gisbert","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1572-0241.2006.00463.x","article-title":"Factors associated with the development of intestinal strictures or obstructions in patients with Crohn\u2019s disease","volume":"101","author":"Lichtenstein","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","article-title":"Efficacy of adalimumab in patients with Crohn\u2019s disease and symptomatic small bowel stricture: A multicentre, prospective, observational cohort (CREOLE) study","volume":"67","author":"Bouhnik","year":"2018","journal-title":"Gut"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/2050640620947579","article-title":"Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn\u2019s disease","volume":"8","author":"Hoyo","year":"2020","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/ecco-jcc\/jjad181","article-title":"De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review","volume":"18","author":"Gisbert","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S2468-1253(22)00434-4","article-title":"Increased versus conventional adalimumab dose interval for patients with Crohn\u2019s disease in stable remission (LADI): A pragmatic, open-label, non-inferiority, randomised controlled trial","volume":"8","author":"Jansen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_227","first-page":"680","article-title":"The risk of venous thromboembolic events in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"34","author":"Arvanitakis","year":"2021","journal-title":"Ann. Gastroenterol."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Zhang, H., and Wang, X. (2021). Risk Factors of Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.693927"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/j.1572-0241.2008.02052.x","article-title":"Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"McNeil, R., Fredman, D., Eldar, O., Gafter-Gvili, A., and Avni, T. (2024). Venous thromboembolism prophylaxis in inflammatory bowel disease inpatients\u2014Systematic review and meta-analysis. Acta Haematol., 1\u201314.","DOI":"10.1159\/000538086"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/ibd\/izz269","article-title":"Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease","volume":"26","author":"Faye","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.crohns.2013.03.002","article-title":"Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients","volume":"7","author":"Ra","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/00365520410004622","article-title":"Massive haemorrhage induced by low molecular weight heparin in a patient with steroid refractory ulcerative colitis","volume":"39","author":"Kaya","year":"2004","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1007\/s10620-020-06424-x","article-title":"Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry","volume":"66","author":"Algaba","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/ibd\/izaa359","article-title":"Ocular Manifestations of Inflammatory Bowel Disease","volume":"27","author":"Shah","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1572-0241.2008.01846.x","article-title":"Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease","volume":"103","author":"Gisbert","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s40265-013-0131-2","article-title":"Current management of iron deficiency anemia in inflammatory bowel diseases: A practical guide","volume":"73","author":"Gomollon","year":"2013","journal-title":"Drugs"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"Dignass","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1365-2036.2006.03146.x","article-title":"Systematic review: Managing anaemia in Crohn\u2019s disease","volume":"24","author":"Kulnigg","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_241","first-page":"22","article-title":"Prevalence of iron deficiency without anaemia in inflammatory bowel disease and impact on health-related quality of life","volume":"41","author":"Benitez","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/bmj.326.7399.1124","article-title":"Iron supplementation for unexplained fatigue in non-anaemic women: Double blind randomised placebo controlled trial","volume":"326","author":"Verdon","year":"2003","journal-title":"BMJ"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archpedi.160.11.1108","article-title":"Double burden of iron deficiency in infancy and low socioeconomic status: A longitudinal analysis of cognitive test scores to age 19 years","volume":"160","author":"Lozoff","year":"2006","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0140-6736(96)02341-0","article-title":"Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls","volume":"348","author":"Bruner","year":"1996","journal-title":"Lancet"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"676S","DOI":"10.1093\/jn\/131.2.676S","article-title":"Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship","volume":"131","author":"Haas","year":"2001","journal-title":"J. Nutr."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1016\/j.amjmed.2003.12.007","article-title":"Anemia and its clinical consequences in patients with chronic diseases","volume":"116","author":"Goodnough","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00054725-200005000-00013","article-title":"Anemia in IBD: The overlooked villain","volume":"6","author":"Gasche","year":"2000","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/gut.2003.035758","article-title":"Iron, anaemia, and inflammatory bowel diseases","volume":"53","author":"Gasche","year":"2004","journal-title":"Gut"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1016\/j.amjmed.2003.12.011","article-title":"Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature","volume":"116","author":"Wilson","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.MIB.0000196646.64615.db","article-title":"Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients","volume":"12","author":"Wells","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ibd.20925","article-title":"Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement","volume":"15","author":"Gisbert","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"782","DOI":"10.7326\/0003-4819-126-10-199705150-00006","article-title":"Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial","volume":"126","author":"Gasche","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.MIB.0000191670.04605.e7","article-title":"Impact of chronic conditions on quality of life in patients with inflammatory bowel disease","volume":"12","author":"Pizzi","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1053\/j.gastro.2005.12.051","article-title":"Treatment of iron deficiency","volume":"130","author":"Rockey","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjmed.2005.01.065","article-title":"Are we giving too much iron? Low-dose iron therapy is effective in octogenarians","volume":"118","author":"Rimon","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1542\/peds.108.3.613","article-title":"Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia","volume":"108","author":"Zlotkin","year":"2001","journal-title":"Pediatrics"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ajcn\/78.1.145","article-title":"Efficacy and tolerability of low-dose iron supplements during pregnancy: A randomized controlled trial","volume":"78","author":"Makrides","year":"2003","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.amjmed.2008.07.012","article-title":"Individualized treatment for iron-deficiency anemia in adults","volume":"121","author":"Alleyne","year":"2008","journal-title":"Am. J. Med."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/00365520310000771","article-title":"Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease","volume":"38","author":"Erichsen","year":"2003","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2036.2005.02652.x","article-title":"Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease","volume":"22","author":"Erichsen","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2036.2005.02700.x","article-title":"Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: A prospective, comparative trial","volume":"22","author":"Tsironi","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MOG.0b013e32835bdc2e","article-title":"Intravenous iron in inflammatory bowel diseases","volume":"29","author":"Gomollon","year":"2013","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apt.12616","article-title":"Systematic review with meta-analysis: Inflammatory bowel disease in the elderly","volume":"39","author":"Gisbert","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_265","first-page":"415","article-title":"Myths and Misconceptions in the Management of Elderly Patients with Inflammatory Bowel Disease","volume":"17","author":"Katz","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/ecco-jcc\/jjw054","article-title":"Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease","volume":"10","author":"Ananthakrishnan","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/apt.14494","article-title":"Phenotype and natural history of elderly onset inflammatory bowel disease: A multicentre, case-control study","volume":"47","author":"Manosa","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2012-303864","article-title":"Natural history of elderly-onset inflammatory bowel disease: A population-based cohort study","volume":"63","author":"Charpentier","year":"2014","journal-title":"Gut"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1007\/s10620-012-2083-x","article-title":"Geriatric inflammatory bowel disease: Phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity","volume":"57","author":"Juneja","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1007\/s10620-010-1397-9","article-title":"Biologic agent use varies inversely with age at diagnosis in Crohn\u2019s disease","volume":"55","author":"Feagins","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/ajg.2016.433","article-title":"Crohn\u2019s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated with Adalimumab","volume":"111","author":"Osterman","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/apt.13294","article-title":"Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease","volume":"42","author":"Lobaton","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/ecco-jcc\/jjaa012","article-title":"Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients","volume":"14","author":"Smits","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/ecco-jcc\/jjad001","article-title":"ECCO Topical Review on Biological Treatment Cycles in Crohn\u2019s Disease","volume":"17","author":"Noor","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world Pattern of Biologic Use in Patients with Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.15692","article-title":"Systematic review with meta-analysis: Biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease","volume":"51","author":"Piovani","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cgh.2020.04.070","article-title":"Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients with Ulcerative Colitis: Patient-Level Pooled Analysis of Data from Randomized Trials","volume":"19","author":"Cheng","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/ecco-jcc\/jjab213","article-title":"Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry","volume":"16","author":"Calafat","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_280","first-page":"263","article-title":"European Crohn\u2019s and Colitis Organisation Topical Review on IBD in the Elderly","volume":"11","author":"Sturm","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1052-5157(02)00010-7","article-title":"Endoscopy in the pregnant patient with inflammatory bowel disease","volume":"12","author":"Katz","year":"2002","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/BF02065437","article-title":"Multicenter, multiyear study of safety and efficacy of flexible sigmoidoscopy during pregnancy in 24 females with follow-up of fetal outcome","volume":"40","author":"Cappell","year":"1995","journal-title":"Dig. Dis. Sci."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.giec.2006.01.009","article-title":"Flexible sigmoidoscopy and colonoscopy during pregnancy","volume":"16","author":"Siddiqui","year":"2006","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ecco-jcc\/jjv079","article-title":"A prospective study of the safety of lower gastrointestinal endoscopy during pregnancy in patients with inflammatory bowel disease","volume":"9","author":"Zelinkova","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"De Lima, A., Galjart, B., Wisse, P.H.A., Bramer, W.M., and van der Woude, C.J. (2015). Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child?\u2014A systematic review. BMC Gastroenterol., 15.","DOI":"10.1186\/s12876-015-0244-z"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/BF02100127","article-title":"A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups","volume":"41","author":"Cappell","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/j.crohns.2012.09.010","article-title":"Inflammatory bowel disease and pregnancy: Lack of knowledge is associated with negative views","volume":"7","author":"Selinger","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jgh3.12442","article-title":"Addressing pregnancy-related concerns in women with inflammatory bowel disease: Insights from the patient\u2019s perspective","volume":"5","author":"Flanagan","year":"2021","journal-title":"JGH Open"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2013.171","article-title":"Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease","volume":"108","author":"Gisbert","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2014.959489","article-title":"How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?","volume":"13","author":"Chaparro","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.dld.2023.08.054","article-title":"New drugs for the treatment of IBD during conception, pregnancy, and lactation","volume":"56","author":"Pugliese","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(24)00052-7","article-title":"Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation","volume":"403","author":"Nielsen","year":"2024","journal-title":"Lancet"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women with Inflammatory Bowel Disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-Term Safety of In Utero Exposure to Anti-TNFalpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous Anti-TNFalpha Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/ibd\/izab206","article-title":"Risk Factors for Postpartum Disease Activity in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"28","author":"Malhi","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1091581819864105","article-title":"Evaluation of the Developmental Toxicity of Vedolizumab, an alpha(4)beta(7) Receptor Antagonist, in Rabbit and Nonhuman Primate","volume":"38","author":"Crawford","year":"2019","journal-title":"Int. J. Toxicol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2017.08.067","article-title":"Vedolizumab Concentrations in the Breast Milk of Nursing Mothers with Inflammatory Bowel Disease","volume":"154","author":"Julsgaard","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ecco-jcc\/jjx120","article-title":"Vedolizumab Levels in Breast Milk of Nursing Mothers with Inflammatory Bowel Disease","volume":"12","author":"Lahat","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40262-021-00985-4","article-title":"Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease","volume":"60","author":"Sun","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40780-022-00249-8","article-title":"Ustekinumab during pregnancy and lactation: Drug levels in maternal serum, cord blood, breast milk, and infant serum","volume":"8","author":"Saito","year":"2022","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ajg.2011.295","article-title":"Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab","volume":"107","author":"Moses","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1007\/s10620-015-3631-y","article-title":"Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis","volume":"60","author":"Nguyen","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.vaccine.2017.03.080","article-title":"Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis","volume":"35","author":"Jiang","year":"2017","journal-title":"Vaccine"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.14309\/ajg.0000000000000289","article-title":"High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults with Inflammatory Bowel Disease","volume":"114","author":"Pittet","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.3748\/wjg.v23.i42.7644","article-title":"Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease","volume":"23","author":"Nguyen","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MPG.0000000000002810","article-title":"Immune Response to Vaccination in Children and Young People with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"71","author":"Dembinski","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ecco-jcc\/jjad005","article-title":"Vaccines in Children Exposed to Biological Agents In Utero and\/or During Breastfeeding: Are They Effective and Safe?","volume":"17","author":"Gisbert","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Barenbrug, L., Groen, M.T., Hoentjen, F., van Drongelen, J., Reek, J., Joosten, I., de Jong, E., and van der Molen, R.G. (2021). Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-alpha during pregnancy: A systemic review and meta-analysis. J. Autoimmun., 122.","DOI":"10.1016\/j.jaut.2021.102676"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.vaccine.2022.03.041","article-title":"Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysis","volume":"40","author":"Gertosio","year":"2022","journal-title":"Vaccine"},{"key":"ref_315","doi-asserted-by":"crossref","unstructured":"Esposito, S., Antoniol, G., Labate, M., Passadore, L., Alvisi, P., Dacco, V., Ghizzi, C., Colombo, C., and Principi, N. (2021). Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines, 9.","DOI":"10.3390\/vaccines9050487"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/gutjnl-2019-319129","article-title":"Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life","volume":"70","author":"Kanis","year":"2021","journal-title":"Gut"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/ibd\/izab266","article-title":"Safety of Immunizations for the Adult Patient with Inflammatory Bowel Disease-A Systematic Review and Meta-analysis","volume":"28","author":"Desalermos","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_318","doi-asserted-by":"crossref","unstructured":"Weiss, B., Ben-Horin, S., Lev, A., Broide, E., Yavzori, M., Lahat, A., Kopylov, U., Picard, O., Eliakim, R., and Ron, Y. (2022). Immune function in newborns with in-utero exposure to anti-TNFalpha therapy. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.935034"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ecco-jcc\/jjy053","article-title":"Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero","volume":"12","author":"Kanis","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.dld.2021.05.015","article-title":"Vaccinations in patients with inflammatory bowel disease","volume":"53","author":"Macaluso","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1093\/rheumatology\/keac141","article-title":"A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero","volume":"61","author":"Goulden","year":"2022","journal-title":"Rheumatology"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2352-4642(23)00136-0","article-title":"Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: A prospective cohort study from the Canadian Immunization Research Network","volume":"7","author":"Fitzpatrick","year":"2023","journal-title":"Lancet Child. Adolesc. Health"},{"key":"ref_324","doi-asserted-by":"crossref","unstructured":"The Lancet Gastroenterology Hepatology (2022). Opacity over live vaccines in infants exposed to infliximab. Lancet Gastroenterol. Hepatol., 7, 379.","DOI":"10.1016\/S2468-1253(22)00095-4"},{"key":"ref_325","unstructured":"(2024, June 17). Available online: https:\/\/www.entis-org.eu\/wp-content\/uploads\/2022\/07\/Position-statement-from-the-ENTIS-Scientific-Committee_Infliximab_Final-1.7.22.pdf."},{"key":"ref_326","doi-asserted-by":"crossref","unstructured":"Selinger, C.P., Bel Kok, K., Limdi, J.K., Kent, A., Cooney, R., and Nelson-Piercy, C. (2022). Live vaccinations for infants exposed to maternal infliximab in utero and via breast milk\u2014The need for nuanced decision making. BMJ Open Gastroenterol., 9.","DOI":"10.1136\/bmjgast-2022-001029"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.crohns.2013.09.003","article-title":"Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease","volume":"8","author":"Grosen","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/MCG.0b013e31825f2807","article-title":"Infliximab and adalimumab use during breastfeeding","volume":"46","author":"Fritzsche","year":"2012","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_329","doi-asserted-by":"crossref","unstructured":"Chaparro, M., Donday, M.G., Abad-Santos, F., Martin de Carpi, F.J., Macia-Martinez, M.A., Montero, D., Acosta, D., Brenes, Y., and Gisbert, J.P. (2021). The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: The DUMBO registry study protocol of GETECCU. Therap. Adv. Gastroenterol., 14.","DOI":"10.1177\/17562848211018097"},{"key":"ref_330","first-page":"757","article-title":"Live vaccines in children exposed to biological agents for IBD in utero and\/or during breastfeeding: Are they safe? Results from the DUMBO registry of GETECCU","volume":"10","author":"Chaparro","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41395-018-0057-0","article-title":"Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry","volume":"113","author":"Ordas","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: A randomised controlled, open-label, multicentre trial","volume":"2","author":"Ponsioen","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S2468-1253(20)30117-5","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: Retrospective long-term follow-up of the LIR!C trial","volume":"5","author":"Stevens","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/gutjnl-2018-317539","article-title":"Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn\u2019s disease: The LIR!C Trial","volume":"68","author":"Stevens","year":"2019","journal-title":"Gut"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2023.05.051","article-title":"Early Ileocecal Resection for Crohn\u2019s Disease Is Associated with Improved Long-term Outcomes Compared with Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study","volume":"165","author":"Agrawal","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br. Med. J."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.3748\/wjg.14.5504","article-title":"Severe ulcerative colitis: At what point should we define resistance to steroids?","volume":"14","author":"Esteve","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/bjs.6874","article-title":"Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications","volume":"97","author":"Randall","year":"2010","journal-title":"Br. J. Surg."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ecco-jcc\/jju028","article-title":"Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn\u2019s disease: A meta-analysis of observational studies","volume":"9","author":"Huang","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_340","doi-asserted-by":"crossref","unstructured":"Law, C.C., Bell, C., Koh, D., Bao, Y., Jairath, V., and Narula, N. (2020). Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database Syst. Rev., 10.","DOI":"10.1002\/14651858.CD013256"},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.4240\/wjgs.v15.i11.2579","article-title":"Risk and management of post-operative infectious complications in inflammatory bowel disease: A systematic review","volume":"15","author":"Mowlah","year":"2023","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0016-5085(03)00883-7","article-title":"Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients","volume":"125","author":"Aberra","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/bjs.5375","article-title":"Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators","volume":"93","author":"Subramanian","year":"2006","journal-title":"Br. J. Surg."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crohns.2013.01.014","article-title":"Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis","volume":"7","author":"Billioud","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/apt.12313","article-title":"Meta-analysis: Peri-operative anti-TNFalpha treatment and post-operative complications in patients with inflammatory bowel disease","volume":"37","author":"Narula","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/ibd\/izy246","article-title":"Meta-Analysis: The Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn\u2019s Disease","volume":"25","author":"Xu","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_347","doi-asserted-by":"crossref","unstructured":"Quaresma, A.B., Yamamoto, T., and Kotze, P.G. (2020). Biologics and surgical outcomes in Crohn\u2019s disease: Is there a direct relationship?. Therap. Adv. Gastroenterol., 13.","DOI":"10.1177\/1756284820931738"},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14423\/SMJ.0000000000001214","article-title":"Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD","volume":"114","author":"Moosvi","year":"2021","journal-title":"South. Med. J."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.surge.2020.09.001","article-title":"Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review","volume":"19","author":"Byrne","year":"2021","journal-title":"Surgeon"},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/DCR.0000000000003222","article-title":"Impact of Biologics and Small-Molecule Agents on Postoperative Complications in IBD: A Systematic Review","volume":"67","author":"Lee","year":"2024","journal-title":"Dis. Colon. Rectum"},{"key":"ref_351","doi-asserted-by":"crossref","unstructured":"Garcia, M.J., Rivero, M., Miranda-Bautista, J., Baston-Rey, I., Mesonero, F., Leo-Carnerero, E., Casas-Deza, D., Cagigas Fernandez, C., Martin-Cardona, A., and El Hajra, I. (2021). Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194402"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ecco-jcc\/jjz187","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Surgical Treatment","volume":"14","author":"Adamina","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_353","doi-asserted-by":"crossref","unstructured":"El-Hussuna, A., Qvist, N., Zangenberg, M.S., Langkilde, A., Siersma, V., Hjort, S., and Gogenur, I. (2018). No effect of anti-TNF-alpha agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: A prospective multi-center pilot study. BMC Surg., 18.","DOI":"10.1186\/s12893-018-0425-0"},{"key":"ref_354","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: A review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_355","doi-asserted-by":"crossref","unstructured":"Gisbert, J.P., and Chaparro, M. (2021). Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. J. Clin. Med., 10.","DOI":"10.3390\/jcm10225318"},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40265-023-01916-2","article-title":"Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn\u2019s Disease","volume":"83","author":"Gisbert","year":"2023","journal-title":"Drugs"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/ecco-jcc\/jjad053","article-title":"Results of the Eighth Scientific Workshop of ECCO: Prevention and Treatment of Postoperative Recurrence in Patients with Crohn\u2019s Disease Undergoing an Ileocolonic Resection with Ileocolonic Anastomosis","volume":"17","author":"Ferrante","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_358","first-page":"281","article-title":"Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn\u2019s Disease Recurrence","volume":"11","author":"Collins","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00595-018-1634-y","article-title":"Postoperative adalimumab maintenance therapy for Japanese patients with Crohn\u2019s disease: A single-center, single-arm phase II trial (CCOG-1107 study)","volume":"48","author":"Asada","year":"2018","journal-title":"Surg. Today"},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5217\/ir.2018.16.1.75","article-title":"Efficacy of restarting anti-tumor necrosis factor alpha agents after surgery in patients with Crohn\u2019s disease","volume":"16","author":"Hiraoka","year":"2018","journal-title":"Intest. Res."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5217\/ir.2021.00018","article-title":"Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn\u2019s disease","volume":"20","author":"Buisson","year":"2022","journal-title":"Intest. Res."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2019.07.025","article-title":"Rate of Reoperation Decreased Significantly After Year 2002 in Patients with Crohn\u2019s Disease","volume":"18","author":"Shinagawa","year":"2020","journal-title":"Clin Gastroenterol. Hepatol."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000375302","article-title":"Combination therapy with infliximab and thiopurine compared to infliximab monotherapy in maintaining remission of postoperative Crohn\u2019s disease","volume":"91","author":"Sakuraba","year":"2015","journal-title":"Digestion"},{"key":"ref_364","first-page":"O39","article-title":"Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn\u2019s disease: A multicentre observational study","volume":"19","author":"Kotze","year":"2017","journal-title":"Colorectal Dis."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/apt.14944","article-title":"Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn\u2019s disease: Results from a prospective cohort study","volume":"48","author":"Auzolle","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ibd\/izz084","article-title":"Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry","volume":"25","author":"Canete","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1016\/j.cgh.2021.10.021","article-title":"Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn\u2019s Disease: A Pooled Analysis of 6 Trials","volume":"20","author":"Beelen","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"414","DOI":"10.5009\/gnl210062","article-title":"Continued Postoperative Use of Tumor Necrosis Factor-alpha Inhibitors for the Prevention of Crohn\u2019s Disease Recurrence","volume":"16","author":"Yu","year":"2022","journal-title":"Gut Liver"},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/ecco-jcc\/jjac100","article-title":"Endoscopic Postoperative Recurrence in Crohn\u2019s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study","volume":"16","author":"Yanai","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.dld.2022.09.004","article-title":"Prevention of post-operative recurrence of Crohn\u2019s disease among patients with prior anti-TNFalpha failure: A retrospective multicenter study","volume":"55","author":"Altwegg","year":"2023","journal-title":"Dig. Liver Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4795\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:36:45Z","timestamp":1760110605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":371,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13164795"],"URL":"https:\/\/doi.org\/10.3390\/jcm13164795","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}